AvalehtBSX • NYSE
add
Boston Scientific Corp
Viimane sulgemishind
98,85 $
Tänane vahemik
97,73 $ - 99,33 $
Aasta vahemik
85,03 $ - 109,50 $
Turuväärtus
145,77 mld USD
Keskmine maht
9,35 mln
P/E suhe
52,64
Dividendimäär
-
Põhibörs
NYSE
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | 5,06 mld | 20,34% |
Põhitegevusega seonduv kulu | 2,48 mld | 14,08% |
Puhastulu | 755,00 mln | 60,98% |
Puhaskasumimarginaal | 14,91 | 33,84% |
Puhaskasum aktsia kohta | 0,75 | 19,05% |
EBITDA | 1,43 mld | 39,84% |
Tõhus maksumäär | 19,51% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 534,00 mln | −78,66% |
Kogu vara | — | — |
Kõik kohustused | — | — |
Kogu omakapital | 22,65 mld | — |
Emiteeritud aktsiate arv | 1,48 mld | — |
Hinna ja väärtuse suhe P/B | 6,53 | — |
Varade tasuvus | — | — |
Kapitali tasuvus | 7,90% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 755,00 mln | 60,98% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
Tegevjuht
Asutatud
1979
Veebisait
Töötajate arv
53 000